Adalimumab biosimilar (NeuClone/Serum Institute of India)

N/A

Report date: 2024/10/30 11:26:24

Base Information

Drug NameAdalimumab biosimilar (NeuClone/Serum Institute of India)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNeucloneSerum Institute Of India Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeucloneSerum Institute Of India Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A